Cassava Sciences Inc(SAVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.2 | Insider Own | 11.72% | Shs Outstand | 48.3M | Perf Week | 7.21% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | 36.79% | Insider Trans | 9.49% | Shs Float | 42.6M | Perf Month | 17.24% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.3 | Inst Own | 28.56% | Short Float | 16.7% | Perf Quarter | -25.39% |
| Income | -0.11B | P/S | - | EPS this Y | -32.19% | Inst Trans | -0.08% | Short Ratio | 8.56 | Perf Half Y | 11.21% |
| Sales | 0.00B | P/B | 1.41 | EPS next 5Y | - | ROA | -59.99% | Short Interest | 7.12M | Perf YTD | 20.2% |
| Book/sh | 1.69 | P/C | 1.08 | EPS past 3/5Y | -21.17% -40.61% | ROE | -85.44% | 52W High | -52.21% ($4.98) | Perf Year | -10.86% |
| Cash/sh | 2.2 | P/FCF | - | Sales past 3/5Y | - | ROIC | -129.99% | 52W Low | 106.96% ($1.15) | Perf 3Y | -90.44% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -505.96% | Gross Margin | - | Volatility(W/M) | 5.67% 6.42% | Perf 5Y | -95.39% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.15 | Perf 10Y | -83.08% |
| Dividend Ex-Date | 2012/12/13 | Quick Ratio | 2.27 | EPS Q/Q | 61.59% | Profit Margin | - | RSI (14) | 58.06 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.27 | Sales Q/Q | - | SMA20 | 8.65% ($2.19) | Beta | -0.82 | Target Price | $8 |
| Payout | - | Debt/Eq | 0 | Earnings | 2025/11/12 | SMA50 | 12.22% ($2.12) | Rel Volume | 2.48 | Prev Close | $2.12 |
| Employees | 30 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 18.52% - | SMA200 | -5.35% ($2.51) | Avg Volume(3M) | 0.83M | Price | $2.38 |
| IPO | 2000/7/14 | Option/Short | Yes/Yes | Trades | 6036 | Volume | 2,060,741 | Change | 12.26% |
🧠 Cassava Sciences (SAVA) is a US clinical-stage biotechnology company that focuses its core capabilities on developing oral small-molecule drug candidates for the treatment of devastating neurodegenerative diseases such as Alzheimer's disease.
Over the past 1 year, roughly in the middle
52% below its 1-year high.
Traded more than usual. That is 248% of its average volume.
SAVA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -32.2% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -95.4%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 28.6%.
Tap to view numbers
It ranks #345 of 598 in the industry
Based on market cap of $115M.
ENGN#342 enGene Therapeutics Inc $117M PER - 
OKUR#343 OnKure Therapeutics Inc $116M PER - 
NERV#344 Minerva Neurosciences Inc $116M PER - SAVA#345 Cassava Sciences Inc $115M PER - 
VYGR#345 Voyager Therapeutics Inc $115M PER - 
FAQ
What kind of company is SAVA?
SAVA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SAVA?
The market cap of SAVA is approximately $115M, ranking 4,388 within its sector.
What is the 52-week high and low for SAVA?
SAVA has recorded a 52-week high of $4.98 and a low of $1.15.
